Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Viral Hepatitis Studies Influencing My Practice Following EASL 2022—Audio Recap

June 22-26, 2022; London, United Kingdom
Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from EASL 2022, including novel therapeutics for HBV, HBV cure data, therapeutic updates for HDV, and HCV treatment for treatment-experienced patients.
Stefan Zeuzem, MD
Released: July 6, 2022

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

  • Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
  • HBV cure from the Everest Project in China
  • HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
  • HCV retreatment in patients with prior direct-acting antiviral therapy failure

Information on this Educational Activity


Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk, and Sobi and fees for non-CME/CE services from AbbVie, Gilead Sciences, and MSD.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.

Related Content

Grace Wong, MD: use of an interactive decision support tool to guide screening for and treatment of HDV, from Clinical Care Options (CCO)

Grace LH Wong, MD Released: September 12, 2022

Dr Paul Kwo discusses evolving treatment options for hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Paul Y. Kwo, MD Released: August 2, 2022

Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)

person default Joseph (Patient) Maria Buti, MD person default Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings